Shares of Horizon Pharma PLC (NASDAQ:HZNP) have earned a consensus recommendation of “Buy” from the fifteen brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $19.18.
Several equities analysts recently issued reports on HZNP shares. Mizuho upgraded Horizon Pharma from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $12.00 to $18.00 in a research report on Friday, January 12th. Jefferies Group boosted their price objective on Horizon Pharma from $16.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, November 7th. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price objective on shares of Horizon Pharma in a research report on Sunday, October 22nd. ValuEngine upgraded Horizon Pharma from a “hold” rating to a “buy” rating in a research report on Monday, October 16th. Finally, Cantor Fitzgerald set a $17.00 price objective on Horizon Pharma and gave the company a “buy” rating in a research report on Friday, December 1st.
Shares of Horizon Pharma (HZNP) traded up $0.29 on Tuesday, hitting $14.05. The company had a trading volume of 1,083,900 shares, compared to its average volume of 1,740,629. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52. Horizon Pharma has a 1-year low of $9.45 and a 1-year high of $17.69. The firm has a market cap of $2,300.00, a price-to-earnings ratio of -4.62, a PEG ratio of 0.64 and a beta of 1.35.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HZNP. Paulson & CO. Inc. bought a new stake in Horizon Pharma in the 2nd quarter valued at approximately $58,584,000. Ameriprise Financial Inc. lifted its stake in Horizon Pharma by 419.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,127,694 shares of the biopharmaceutical company’s stock valued at $26,979,000 after acquiring an additional 1,717,841 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Horizon Pharma by 18.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 7,433,330 shares of the biopharmaceutical company’s stock valued at $94,254,000 after acquiring an additional 1,167,722 shares in the last quarter. State Street Corp lifted its stake in Horizon Pharma by 12.0% in the 2nd quarter. State Street Corp now owns 4,906,307 shares of the biopharmaceutical company’s stock valued at $58,241,000 after acquiring an additional 524,187 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Horizon Pharma by 1,865.4% in the 3rd quarter. Principal Financial Group Inc. now owns 399,132 shares of the biopharmaceutical company’s stock valued at $5,060,000 after acquiring an additional 378,824 shares in the last quarter. Hedge funds and other institutional investors own 85.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/13/horizon-pharma-plc-hznp-given-average-rating-of-buy-by-brokerages.html.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.